AAAAAA

   
Results: 1-15 |
Results: 15
Pharmacokinetic properties of 2 '-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats
Authors: Geary, RS Watanabe, TA Truong, L Freier, S Lesnik, EA Sioufi, NB Sasmor, H Manoharan, M Levin, AA
Citation: Rs. Geary et al., Pharmacokinetic properties of 2 '-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats, J PHARM EXP, 296(3), 2001, pp. 890-897
Absolute bioavailability of 2 '-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats
Authors: Geary, RS Khatsenko, O Bunker, K Crooke, R Moore, M Burckin, T Truong, L Sasmor, H Levin, AA
Citation: Rs. Geary et al., Absolute bioavailability of 2 '-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats, J PHARM EXP, 296(3), 2001, pp. 898-904
Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice
Authors: Yu, RZ Zhang, H Geary, RS Graham, M Masarjian, L Lemonidis, K Crooke, R Dean, NM Levin, AA
Citation: Rz. Yu et al., Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice, J PHARM EXP, 296(2), 2001, pp. 388-395
Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey
Authors: Yu, RZ Geary, RS Leeds, JM Watanabe, T Moore, M Fitchett, J Matson, J Burckin, T Templin, MV Levin, AA
Citation: Rz. Yu et al., Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey, J PHARM SCI, 90(2), 2001, pp. 182-193
A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma
Authors: Cunningham, CC Holmlund, JT Geary, RS Kwoh, TJ Dorr, A Johnston, JF Monia, B Nemunaitis, J
Citation: Cc. Cunningham et al., A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma, CANCER, 92(5), 2001, pp. 1265-1271
Pharmacokinetic properties in animals
Authors: Geary, RS Yu, RZ Leeds, JM Watanabe, TA Henry, SP Levin, AA Templin, MV
Citation: Rs. Geary et al., Pharmacokinetic properties in animals, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 119-154
Pharmacokinetic properties in humans
Authors: Yu, RZ Geary, RS Watanabe, TA Levin, AA Schoenfeld, SL
Citation: Rz. Yu et al., Pharmacokinetic properties in humans, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, 2001, pp. 183-200
Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotidefollowing inhalation delivery to lung in mice
Authors: Templin, MV Levin, AA Graham, MJ Aberg, PM Axelsson, BI Butler, M Geary, RS Bennett, CF
Citation: Mv. Templin et al., Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotidefollowing inhalation delivery to lung in mice, ANTISENSE N, 10(5), 2000, pp. 359-368
Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length
Authors: Khatsenko, O Morgan, R Truong, L York-Defalco, C Sasmor, H Conklin, B Geary, RS
Citation: O. Khatsenko et al., Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length, ANTISENSE N, 10(1), 2000, pp. 35-44
A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
Authors: Cunningham, CC Holmlund, JT Schiller, JH Geary, RS Kwoh, TJ Dorr, A Nemunaitis, J
Citation: Cc. Cunningham et al., A phase I trial of c-raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer, CLIN CANC R, 6(5), 2000, pp. 1626-1631
Antisense oligonucleotide-based therapeutics
Authors: Bennett, CF Butler, M Cook, PD Geary, RS Levin, AA Mehta, R Teng, CL Deshmukh, H Tillman, L Hardee, G
Citation: Cf. Bennett et al., Antisense oligonucleotide-based therapeutics, GENE THERAPY, 2000, pp. 305-332
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
Authors: Yuen, AR Halsey, J Fisher, GA Holmlund, JT Geary, RS Kwoh, TJ Dorr, A Sikic, BI
Citation: Ar. Yuen et al., Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer, CLIN CANC R, 5(11), 1999, pp. 3357-3363
Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes
Authors: Yu, RZ Geary, RS Leeds, JM Watanabe, T Fitchett, JR Matson, JE Mehta, R Hardee, GR Templin, MV Huang, K Newman, MS Quinn, Y Uster, P Zhu, G Working, PK Horner, M Nelson, J Levin, AA
Citation: Rz. Yu et al., Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes, PHARM RES, 16(8), 1999, pp. 1309-1315
A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue
Authors: Geary, RS Matson, J Levin, AA
Citation: Rs. Geary et al., A nonradioisotope biomedical assay for intact oligonucleotide and its chain-shortened metabolites used for determination of exposure and elimination half-life of antisense drugs in tissue, ANALYT BIOC, 274(2), 1999, pp. 241-248
Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys
Authors: Monteith, DK Geary, RS Leeds, JM Johnston, J Monia, BP Levin, AA
Citation: Dk. Monteith et al., Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys, TOXICOL SCI, 46(2), 1998, pp. 365-375
Risultati: 1-15 |